Document is current

Documents that mention this clinical trial

Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence
https://doi.org/10.1136/bmjopen-2024-090376

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation
https://doi.org/10.1136/heartjnl-2015-308887

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
https://doi.org/10.1016/j.ahj.2013.05.016

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
https://doi.org/10.1136/openhrt-2020-001471

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
https://doi.org/10.1136/heartjnl-2018-313351

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
https://doi.org/10.1016/s0140-6736(16)00741-8

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial
https://doi.org/10.1007/s11239-019-01823-y

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
https://doi.org/10.1016/j.ahj.2014.09.006

Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
https://doi.org/10.1136/heartjnl-2017-312272

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x

Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial
https://doi.org/10.1016/j.ahj.2013.05.025

Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
https://doi.org/10.1016/j.ahj.2014.06.005

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60986-6

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
https://doi.org/10.1016/j.ahj.2009.07.035

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
https://doi.org/10.1136/openhrt-2018-000908